Dirk Schadendorf, MD, University Hospital Essen

home / authors / dirk-schadendorf-md-university-hospital-essen

Articles

Future Directions in Metastatic Melanoma

Future Directions in Metastatic Melanoma

Axel Hauschild, MD, PhD, University Hospital Schleswig-Holstein;Dirk Schadendorf, MD, University Hospital Essen
February 5th 2021

Read More

Looking at Approved Agents in Metastatic Melanoma

Looking at Approved Agents in Metastatic Melanoma

Axel Hauschild, MD, PhD, University Hospital Schleswig-Holstein;Dirk Schadendorf, MD, University Hospital Essen
January 29th 2021

Read More

Metastatic Melanoma Treatment Decisions

Metastatic Melanoma Treatment Decisions

Axel Hauschild, MD, PhD, University Hospital Schleswig-Holstein;Dirk Schadendorf, MD, University Hospital Essen
January 29th 2021

Read More

Molecular Testing in Metastatic Melanoma

Molecular Testing in Metastatic Melanoma

Axel Hauschild, MD, PhD, University Hospital Schleswig-Holstein;Dirk Schadendorf, MD, University Hospital Essen
January 22nd 2021

Read More

The Role of COVID-19 in Adjuvant Treatment Decisions in Melanoma

The Role of COVID-19 in Adjuvant Treatment Decisions in Melanoma

Axel Hauschild, MD, PhD, University Hospital Schleswig-Holstein;Dirk Schadendorf, MD, University Hospital Essen
January 22nd 2021

Read More

Treatment Goals and Patient Decisions in Melanoma

Treatment Goals and Patient Decisions in Melanoma

Axel Hauschild, MD, PhD, University Hospital Schleswig-Holstein;Dirk Schadendorf, MD, University Hospital Essen
January 15th 2021

Read More

A Look at the KEYNOTE-054 and COMBI-AD Data

A Look at the KEYNOTE-054 and COMBI-AD Data

Axel Hauschild, MD, PhD, University Hospital Schleswig-Holstein;Dirk Schadendorf, MD, University Hospital Essen
January 15th 2021

Read More

Testing and BRAF Mutations in Melanoma

Testing and BRAF Mutations in Melanoma

Axel Hauschild, MD, PhD, University Hospital Schleswig-Holstein;Dirk Schadendorf, MD, University Hospital Essen
January 8th 2021

Read More

Introduction to Melanoma

Introduction to Melanoma

Axel Hauschild, MD, PhD, University Hospital Schleswig-Holstein;Dirk Schadendorf, MD, University Hospital Essen
January 8th 2021

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need